sales@reportocean.com (Bussiness Sales)
+18882123539 (Us - Toll Free)
+919997112116 (Rest Of World)
Dermatomyositis: Epidemiology Forecasting Intelligence

Dermatomyositis: Epidemiology Forecasting Intelligence

Home / Categories / Healthcare
Dermatomyositis: Epidemiology Forecasting Intelligence
Dermatomyositis: Epidemiology Forecasting Intelligence
Report Code
RO1/114/1059

Publish Date
01/Mar/2019

Pages
50-70
PRICE
$ 2500/-
This is a single user license, allowing one specific user access to the product. The product is a PDF.
$ 6000/-
This is an enterprise license, allowing all employees within your organization access to the product. The product is a PDF..
1. Report Introduction
2. Dermatomyositis Epidemiology Overview at a Glance
3. Market Share Distribution of Dermatomyositis
4. Disease Background and Overview: Dermatomyositis
4.1. Introduction
4.2. Signs and Symptoms
4.3. Etiology
4.4. Risk Factors
4.5. Pathophysiology
4.6. Diagnostic Landscape
4.6.1. Diagnostic Practices
4.6.2. Diagnostic Criteria
4.6.3. Diagnostic Recommendations
4.7. Treatment Landscape
4.7.1. Current Treatment Practices
4.7.2. Treatment Algorithm
4.7.3. Treatment Recommendations
5. Dermatomyositis Epidemiology
5.1. Key Findings
5.2. Assumptions & Rationale
5.3. 7MM Epidemiology
6. Epidemiology of Dermatomyositis by Countries
7. United States
7.1. Assumptions and Rationale
7.2. Prevalent/Incident Cases of Dermatomyositis
7.3. Sub-Type Specific cases of Dermatomyositis*
7.4. Sex- Specific Cases of Dermatomyositis*
7.5. Diagnosed Cases of Dermatomyositis
7.6. Treated Cases of Dermatomyositis
8. EU5
8.1. Germany
8.1.1. Assumptions and Rationale
8.1.2. Prevalent/Incident Cases of Dermatomyositis
8.1.3. Sub-Type Specific cases of Dermatomyositis*
8.1.4. Sex- Specific Cases of Dermatomyositis*
8.1.5. Diagnosed Cases of Dermatomyositis
8.1.6. Treated Cases of Dermatomyositis
8.2. France
8.2.1. Assumptions and Rationale
8.2.2. Prevalent/Incident Cases of Dermatomyositis
8.2.3. Sub-Type Specific cases of Dermatomyositis*
8.2.4. Sex- Specific Cases of Dermatomyositis*
8.2.5. Diagnosed Cases of Dermatomyositis
8.2.6. Treated Cases of Dermatomyositis
8.3. United Kingdom
8.3.1. Assumptions and Rationale
8.3.2. Prevalent/Incident Cases of Dermatomyositis
8.3.3. Sub-Type Specific cases of Dermatomyositis*
8.3.4. Sex- Specific Cases of Dermatomyositis*
8.3.5. Diagnosed Cases of Dermatomyositis
8.3.6. Treated Cases of Dermatomyositis
8.4. Spain
8.4.1. Assumptions and Rationale
8.4.2. Prevalent/Incident Cases of Dermatomyositis
8.4.3. Sub-Type Specific cases of Dermatomyositis*
8.4.4. Sex- Specific Cases of Dermatomyositis*
8.4.5. Diagnosed Cases of Dermatomyositis
8.4.6. Treated Cases of Dermatomyositis
8.5. Italy
8.5.1. Assumptions and Rationale
8.5.2. Prevalent/Incident Cases of Dermatomyositis
8.5.3. Sub-Type Specific cases of Dermatomyositis*
8.5.4. Sex- Specific Cases of Dermatomyositis*
8.5.5. Diagnosed Cases of Dermatomyositis
8.5.6. Treated Cases of Dermatomyositis
9. Japan
9.1. Assumptions and Rationale
9.2. Prevalent/Incident Cases of Dermatomyositis
9.3. Sub-Type Specific cases of Dermatomyositis*
9.4. Sex- Specific Cases of Dermatomyositis*
9.5. Diagnosed Cases of Dermatomyositis
9.6. Treated Cases of Dermatomyositis
10. Unmet Needs
Appendix
Report Methodology
Sources Used
Disclaimer
About CmaxInsight
*Indication Specific

Note: Certain sections of the table of contents would vary according to the availability of information.

OUR CLIENTS

500 N Michigan Ave, Suite 600, Chicago, Illinois 60611, UNITED STATES
+18882123539
sales@reportocean.com